An interventional study of High-Protein Beverage (Genius Gourmet Sparkling Protein Water) and Standard Clear Liquid Diet in Diabetes During Pregnancy, sponsored by Medical College of Wisconsin. Recruiting at 1 site in United States. Open to female participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-10-26.
Sponsored by Medical College of Wisconsin · Not applicable, Interventional, and Prevention
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 251 studies in Diabetes, Gestational with a site in United States — 52 open to participants now, 65 under way, 2 of them phase 3. Diabetes, Gestational · United States.
Among the 251 studies in Diabetes, Gestational with a site in United States, this one is the 110th largest by planned enrollment of the 194 interventional ones that give a count, is one of 10 that started in 2026, is one of 154 with no phase, reaches primary completion later than 53 of the 64 other live ones, and was the 245th registered.
878 studies on the registry are indexed under Diabetes, Gestational; 196 are open to participants now.
Browse Diabetes, Gestational studies →52 of the 251 studies in Diabetes, Gestational with a site in United States are open now. Recruiting first, the newest first:
Mayo Clinic · Sites in United States
Ages 20–40 · Women only
Texas A&M University · Sites in United States
Ages 18–45 · Women only · Healthy volunteers
University of Hawaii · Sites in United States
Ages 18+ · Women only
University of California, Davis · Sites in United States
Ages 18+ · Healthy volunteers
California Polytechnic State University-San Luis Obispo · Sites in United States
Ages 18+ · Women only
A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →
Of the 132 Diabetes, Gestational studies recruiting now, 60 (45%) set no upper age limit and 70 (53%) stop at 75 or younger; 12 take children under 18; 60 take healthy volunteers.
This study: 18 Years and older · female · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
251 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 14 · Phase 2 11 · Phase 3 9 · Phase 4 11
First in 2000; this study’s year is marked. 10 started in 2026.
By drug class, each counting the studies that test any of its medicines:
This study's planned enrollment of 60 is below the median of 110 across 563 interventional studies indexed under Diabetes, Gestational.
Median enrollment 80 across the 194 interventional studies, 72 across the 57 observational. Of the 154 that completed or were terminated, 35 (23%) have results posted.
This tab as a report to print or save as PDF → With an account.
10 of 251 have an industry lead sponsor. The 10 most frequent:
Medical College of Wisconsin is the lead sponsor of 550 studies on the registry; 123 are open to participants now.
Of its 76 completed or terminated interventional studies of FDA-regulated products, 58 (76%) have results posted.
Medical College of Wisconsin has 3 studies filed under Diabetes, Gestational — fewer than ten, so there is no comparison to draw.
22 of the studies in Diabetes, Gestational with a site in United States that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT07356180University of Maryland, BaltimorePhysical Acvitiy in Pregnancy | 2026-12 |
| NCT05909046Ohio State UniversityA Randomized Controlled Trial of Diabetes Screening Immediately Postpartum (DIP) and Follow Up PP CARE | 2026-12 |
| NCT05388643University of Massachusetts, WorcesterEarly Detection of Gestational Diabetes Mellitus in Pregnancy | 2026-12-01 |
| NCT07176793University of California, DavisPregnancy and Postpartum Breastfeeding Support for Patients With Gestational Diabetes | 2026-12-30 |
| NCT05124808Indiana UniversityIntensive Glycemic Targets in Overweight and Obese Women With Gestational Diabetes | 2026-12-31 |
Add all 22 to your calendar (.ics) → With an account.
Among the 251 studies in Diabetes, Gestational with a site in United States, from their registry updates:
This tab as a report to print or save as PDF → With an account.
The goal of this study is to learn if high-protein drinks during labor can improve blood sugar control in pregnant women with insulin-treated diabetes. It will also help us learn if this approach is acceptable and well-tolerated by patients. The main questions it aims to answer are:
Researchers will compare women who drink high-protein beverages to women who drink standard clear liquids (like juice, broth, and popsicles) to see if protein drinks help keep blood sugar more stable during labor.
Participants will:
Background and Rationale:
Optimal nutrition during labor for patients with insulin-treated diabetes in pregnancy remains poorly defined. While current guidelines support clear liquid intake during labor, the metabolic effects of different nutritional strategies-particularly high-protein supplementation-have not been studied. Maintaining stable maternal glucose levels during labor is essential to reducing neonatal complications, including hypoglycemia. However, standard clear liquids may cause glucose excursions, while prolonged fasting may contribute to maternal fatigue and metabolic stress.
Continuous glucose monitoring (CGM) technology provides real-time assessment of glucose patterns during labor, offering a novel opportunity to evaluate how targeted nutritional interventions influence maternal glycemic stability. Recent evidence suggests that maternal time above glucose target range during labor is associated with neonatal hypoglycemia, yet no studies have examined whether protein-based oral supplementation can improve intrapartum glucose control compared to standard clear liquids.
Study Objectives:
This pilot randomized controlled trial evaluates the feasibility and metabolic impact of high-protein oral supplementation during labor in patients with insulin-treated gestational or type 2 diabetes undergoing induction of labor. The study aims to:
Study Design:
Sixty participants with insulin-treated gestational diabetes (GDM A2) or type 2 diabetes will be randomized 1:1 to receive either high-protein nutritional supplements (30g protein, 0g carbohydrate) every 4 hours during labor or standard institutional clear liquid diet. All participants will wear a blinded CGM (Abbott Freestyle Libre) from admission through delivery and for up to 7 days postpartum. The primary outcome is percent time above glucose range (>110 mg/dL) during labor. Secondary outcomes include other CGM metrics, maternal fatigue and satisfaction scores, labor outcomes, and neonatal hypoglycemia.
Significance:
This pilot study will generate critical preliminary data on the metabolic effects, patient-centered outcomes, and feasibility of high-protein intrapartum supplementation, informing the design of future larger trials to optimize evidence-based nutritional management during labor for patients with insulin-treated diabetes.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Contraindication
A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Participants will be offered Genius Gourmet Sparkling Protein Water (approximately 30 g protein, 0 g carbohydrate, 0 g fat, 130 kcal per 12-ounce serving) every 4 hours beginning at randomization until delivery. Consumption is voluntary. All participants will wear a blinded CGM from admission through 7 days postpartum.
Dietary Supplement: High-Protein Beverage (Genius Gourmet Sparkling Protein Water) · Device: Continuous Glucose Monitoring (Abbott Freestyle Libre)
Participants will receive standard institutional clear liquid diet (water, ice chips, clear fruit juices, clear carbonated beverages, popsicles, clear broth, gelatin) ad libitum throughout labor per routine institutional practice. All participants will wear a blinded CGM from admission through 7 days postpartum.
Other: Standard Clear Liquid Diet · Device: Continuous Glucose Monitoring (Abbott Freestyle Libre)
Clear, carbonated, commercially available high-protein nutritional supplement containing approximately 30 g protein, 0 g carbohydrate, 0 g fat, and 130 kcal per 12-ounce serving. Offered every 4 hours during labor. Multiple flavors available (participant's choice).
Standard institutional clear liquid diet including water, ice chips, clear fruit juices (e.g., apple juice), clear carbonated beverages (e.g., ginger ale), popsicles, clear broth, and gelatin. Carbohydrate-containing clear liquids permitted per standard practice.
Abbott Freestyle Libre 2 or Libre 3 CGM sensor placed on upper arm upon admission. Sensor remains in place through delivery and up to 7 days postpartum. CGM data blinded to participants and clinical staff during labor.
Percent Time Above Range (TAR >110 mg/dL) During Labor
Percentage of CGM readings exceeding 110 mg/dL during labor, calculated as the proportion of valid CGM readings \>110 mg/dL divided by total valid readings, expressed as a percentage.
Time frame: From admission to delivery (expected ≤72 hours)
Time in Range
Percentage of CGM readings within target range during labor (70-110 mg/dL)
Time frame: From admission to delivery (expected ≤72 hours)
Glycemic Variability
Standard deviation and coefficient of variation of CGM glucose values during labor.
Time frame: From admission to delivery (expected ≤72 hours)
Hyperglycemic Excursions
Number of episodes of CGM glucose \>140 mg/dL, separated by ≥15 minutes below threshold.
Time frame: From admission to delivery (expected ≤72 hours)
Hypoglycemic Events
Number of CGM glucose values \<70 mg/dL during labor.
Time frame: From admission to delivery (expected ≤72 hours)
Total Insulin Use During Labor
Total insulin administered (units)
Time frame: From admission to delivery (expected ≤72 hours)
Maternal Fatigue Score (VAS)
Visual Analog Scale for fatigue (0-10), where higher scores indicate greater fatigue.
Time frame: Admission and every 4 hours until delivery (expected ≤72 hours)
Labor Agentry Scale Score (LAS)
Labor Agentry Scale (LAS), a 29-item validated measure of perceived control during labor. Each item is scored on a 7-point Likert scale. Total scores range from 29 to 203, with higher scores indicating greater perceived control.
Time frame: 24-48 hours postpartum
Birth Satisfaction Scale-Revised Score
A 10-item validated measure of overall birth satisfaction. Each item is scored on a 0-4 scale. Total scores range from 0 to 40, with higher scores indicating greater birth satisfaction.
Time frame: 24-48 hours postpartum
Maternal Emesis
Number of vomiting episodes during labor documented by clinical record or participant report.
Time frame: From admission to delivery (expected ≤72 hours)
Mode of Delivery
Mode of delivery categorized as spontaneous vaginal, operative vaginal, or cesarean delivery.
Time frame: At delivery
Neonatal Hypoglycemia
Blood glucose \<40 mg/dL.
Time frame: First 24 hours of life
Neonatal Intensive Care Unit (NICU) Admission
Admission to neonatal intensive care unit (yes/no).
Time frame: From birth through hospital discharge (expected ≤28 days)
Neonatal Glucose Supplementation
Requirement for oral or IV glucose.
Time frame: First 24 hours of life
Postpartum Time in Range
Percentage of CGM readings within postpartum target range (70-140 mg/dL).
Time frame: Delivery to 7 days postpartum
Composite Maternal Morbidity
Composite maternal morbidity defined as occurrence of any of the following conditions: postpartum hemorrhage requiring intervention such as estimated blood loss \>1000 milliliters (mL) or uterotonics, tranexamic acid, blood transfusion or surgical interventions (dilation and curettage, Bakri, Jada, laparotomy, interventional radiology), endometritis, intraamniotic infection, obstetric anal sphincter injury (OASIS), ICU admission, amniotic fluid embolism, and death.
Time frame: Up to 6 weeks postpartum
Umbilical Cord Blood Gas Values
Umbilical arterial cord blood gas values (pH, partial pressure of carbon dioxide (pCO₂), and base excess)
Time frame: At delivery
Infant Healthcare Utilization
Healthcare utilization including hospitalizations, emergency department visits, urgent care visits, and primary care visits assessed via medical record and parental report.
Time frame: Birth to 1 year of life
Labor Duration
Duration of first, second, and third stages of labor measured in hours
Time frame: From admission to delivery (expected ≤72 hours)
Infant Weight
Infant weight in kilograms
Time frame: Birth to 1 year of life
Infant Length
Infant length in centimeters
Time frame: Birth to 1 year of life
NICU Length of Stay
Duration of NICU hospitalization measured in days.
Time frame: From birth through hospital discharge (expected ≤28 days)
Respiratory Support
Requirement for respiratory support including supplemental oxygen, continuous positive airway pressure (CPAP), or mechanical ventilation (intubation).
Time frame: From birth through hospital discharge (expected ≤28 days)
Neonatal Jaundice Requiring Phototherapy
Need for phototherapy for neonatal hyperbilirubinemia.
Time frame: From birth through hospital discharge (expected ≤28 days)
Neonatal Hypoglycemia Treatment
Requirement for glucose supplementation (oral or intravenous).
Time frame: From birth through hospital discharge (expected ≤28 days)
Neonatal Sepsis
Documented clinical suspicion or laboratory-confirmed neonatal sepsis.
Time frame: From birth through hospital discharge (expected ≤28 days)
Perinatal Death
Fetal or neonatal death occurring from birth through hospital discharge.
Time frame: From birth through hospital discharge (expected ≤28 days)
Neonatal Resuscitation Level
Level of resuscitation at birth categorized as none, stimulation only, positive pressure ventilation, or advanced resuscitation.
Time frame: At delivery
Recruitment Rate
Proportion of eligible patients who consent to participation.
Time frame: Recruitment period (up to 18 months)
Intervention Adherence
Proportion of scheduled supplements consumed (measured as proportion of scheduled doses consumed)
Time frame: From admission to delivery (expected ≤72 hours)
CGM Data Completeness
Proportion of the intrapartum period with valid CGM data
Time frame: From admission to delivery (expected ≤72 hours)
Survey Completion Rate
Proportion of participants completing postpartum surveys (LAS and BSS-R).
Time frame: 48 hours postpartum
Number of Maternal Healthcare Encounters
Number of healthcare encounters including hospitalizations, emergency department visits, urgent care visits, and primary care visits.
Time frame: From hospital discharge to 6 weeks postpartum
Developmental screening
Development assessed using Ages and Stages Questionnaire, Third Edition (ASQ-3), a parent-completed developmental screening tool with five domains (communication, gross motor, fine motor, problem-solving, personal-social). Domain scores range from 0 to 60, with lower scores indicating greater developmental concern. This is a screening tool; scores are interpreted relative to age-specific cutoffs.
Time frame: First year of life
Randomization Success
Proportion of consented patients successfully randomized
Time frame: Recruitment period (up to 18 months)
Protocol Deviations
Number and type of deviations from the study protocol.
Time frame: Recruitment period (up to 18 months)
Retention
Proportion of randomized participants with complete primary outcome data
Time frame: From randomization through delivery hospitalization(expected ≤7 days)
Postpartum CGM Tolerability
Structured questionnaire assessing irritation, comfort, interference, and willingness to reuse CGM using structured Likert-style responses (e.g., none/mild/moderate/severe for irritation; yes/no for willingness to use CGM again). No composite score is generated.
Time frame: Within 7 days postpartum
Postpartum CGM Wear Time
Total postpartum CGM wear time (hours).
Time frame: Delivery to 7 days postpartum
Plan to share: No
No publications or documents are linked to this record.
Started Jul 2026 (actual). Primary completion is estimated for Jul 2028, 24 months after the start.
Of 306 non-industry interventional studies with no phase under Diabetes, Gestational, half reached primary completion within 28 months of starting (the median), counting those still running; a quarter within 13 and three quarters within 48. This study's planned 24 months is below that.
Counting every sponsor, half of 309 studies reached it within 28 months; a quarter within 13 and three quarters within 48.
How these figures are worked out, and which studies are left out of them.
From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗
Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.
Contact study teamGet an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Medical College of Wisconsin →